Topline results were announced from a phase 3 study assessing the immune response following coadministration of Arexvy and Shingrix.

GET MORE AI-GENERATED SIGNALS: September 19, 2024, 20:16 pm ET, BY Jeff W.- Contributor| Editor: Thomas H. Kee Jr. ( Follow ...

GSK plc GSK announced positive topline results from a phase III study evaluating the co-administration of its two marketed ...

If approved, the co-administration of Arexvy and Shingrix could provide a more convenient vaccination regimen for patients ...

GSK (GSK) reached the main goal in a Phase 3 trial for its RSV shot, Arexvy co--administered with Shingles vaccine Shingrix.

British drugmaker GSK said on Wednesday it had agreed to settle two lawsuits in California that claimed its discontinued heartburn drug Zantac caused cancer. GSK does not admit to any liability in ...

GSK plc (GSK, GSK.L) announced positive topline data from the phase 3 trial in adults 50 years and older evaluating the ...

(Reuters) – British drugmaker GSK said on Wednesday its respiratory syncytial virus (RSV) vaccine, when given together with ...

High response rates reported by GSK and iTeos at the 2024 European Society for Medical Oncology Congress offer a ray of light ...